GlassScriptPhysician profile
Hassan Asghar
NPI 1851898704
$1,463.81
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.21 · 2022: $254 · 2023: $493 · 2024: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $339.88 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $225.87 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $149.45 | 2023-2024 | |
| Dexcom, INC. | $131.22 | 2023-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $130.39 | 2022-2024 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $107.80 | 2022-2024 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.93 | 2023-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $61.52 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.26 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $26.48 | 2022-2023 | Quviviq |
| Medtronic, INC. | $24.82 | 2023 | Vanta Adaptivestim |
| Corium, LLC | $23.43 | 2024 | Azstarys |
| Astellas Pharma US INC | $23.07 | 2024 | Veozah |
| Nevro Corp. | $18.68 | 2023 | Senza |
| Otsuka America Pharmaceutical, INC. | $17.85 | 2024 | Abilify Maintena |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $17.75 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $17.57 | 2022 | |
| Abbvie INC. | $14.29 | 2024 | |
| Merck Sharp & Dohme LLC | $13.55 | 2024 | Gardasil, Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hassan Asghar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.